Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to the clinical use of the direct oral inhibitors of blood coagulation factor Xa. Here we show that specific modifications of the substrate-binding aromatic S4 subpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoef, Daniël, Visscher, Koen M., Vosmeer, C. Ruben, Cheung, Ka Lei, Reitsma, Pieter H., Geerke, Daan P., Bos, Mettine H. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597622/
https://www.ncbi.nlm.nih.gov/pubmed/28904343
http://dx.doi.org/10.1038/s41467-017-00647-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597622/
https://www.ncbi.nlm.nih.gov/pubmed/28904343
http://dx.doi.org/10.1038/s41467-017-00647-9

Ejemplares similares